SCHEDULE: Cormorant Asset Management Discloses Rapport Therapeutics Stake

Cormorant Asset Management, LP and Bihua Chen have reported beneficial ownership of 6.19% of Rapport Therapeutics, Inc. common stock as of March 31, 2026.

Summary

• Cormorant Asset Management, LP, acting as an investment adviser to certain funds, and Bihua Chen have jointly filed a Schedule 13G, indicating their beneficial ownership of Rapport Therapeutics, Inc. common stock.
• As of March 31, 2026, the Reporting Persons collectively beneficially own 2,957,521 shares of common stock.
• This ownership represents 6.19% of the total outstanding shares of common stock.
• The filing is made under Rule 13d-1(b) and the securities were acquired and are held in the ordinary course of business, not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership without new strategic information or financial performance data.

Positives

• Cormorant Asset Management, LP and Bihua Chen have disclosed a significant ownership stake, indicating confidence in Rapport Therapeutics.
• The ownership stake of 6.19% suggests a substantial investment in the company.

Risks

• The filing does not explicitly mention any risks, but the nature of Schedule 13G filings implies that the Reporting Persons are not seeking to control the company, which could be interpreted as a lack of intent to actively influence strategic direction.
• The information is based on the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed on March 10, 2026, which may not reflect the most current operational status.

Future Outlook

The filing does not contain forward-looking statements or guidance from the company. It is a disclosure of beneficial ownership.

Management Comments

• "The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment advisers who acquire significant stakes in public companies but do not intend to control them. This filing indicates Cormorant Asset Management's investment strategy in Rapport Therapeutics.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding significant ownership, which can influence market perception and trading activity.
• Management: The filing confirms a substantial passive investment, which may be noted by the board and management in their strategic considerations.

Key Dates

Keywords

Schedule 13G, Rapport Therapeutics, Cormorant Asset Management, Bihua Chen, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser